This thing should move considerably when the new drug app is filed over the next week. The app will get a fair amount of analyst and industry attention. OPK mgt has indicated that it will be filed this quarter.
Sentiment: Strong Buy
Alex Denner has a Ph.D. in biomedical engineering. "Alex Denner knows how to spot biotechnology companies with promising drugs and make sure investments pay off.
Denner’s expertise and persuasive management style have facilitated Icahn’s negotiations with biotechs. The two men first met a decade ago when both invested in ImClone, at a time when most people were writing the company off. ImClone’s founder, Sam Waksal, pleaded guilty in 2002 of insider trading on word that regulatory approval of the company’s main drug would be delayed. ImClone’s shares plummeted 92 percent from a high of $73.83 in December 2001 to $6.11 in September 2002. "
“Activist investors steer away because of health-care’s special characteristics,” he said. “It requires a special knowledge, which Alex has.”
In school, he loved science and math. His father was a mechanical engineer, the same major Denner chose when he was an undergraduate at the Massachusetts Institute of Technology in Cambridge. In graduate school at Yale University in New Haven, Connecticut, he initially intended to study the math involved with the fluid flow of turbulence.
Sentiment: Strong Buy
STOCKHOLM--Sweden's Hennes & Mauritz AB Tuesday reported higher profit for the first quarter, but warned that the stronger dollar will result in gradually increased purchasing costs for the coming quarters of 2015. "Although the strong U.S. dollar will affect ...
he is worth $1b but I'm sure you'll agree that he got that way by making the right long term investments. He wouldn't do this buying if he didn't think he'd make money. Agreed?
That'll give me my 100%. Have Limit Order in for $1.99, but once over $1.63, I'll be tempted to sell. Unfortunately the other 3 stocks I would have, I would have liked to put my 100% in, are already up around 30% themselves.
Was hoping one of my stocks would have doubled, while another was up only around 5%, so I could buy more, and take advantage of the gains in another company.
Will have to decide if I want to put my gains into another one of my stocks already up 30% for the year, or find a couple other stocks that I believe have a chance of doubling in next 12 months. Hopefully I'll have this problem soon.
Not a bad thing of "having" to decide where to put my 100% gain into something else. Just gotta get there first on CCCL. C'mon "decent" earnings, with a "decent" outlook. They do not have to be "great", just decent. A share buyback program would seal the deal. CCCL should be $4.00+ share.
Actually, we are thinking the same. My $12 valuation is based on up-listing by July. Quite frankly, I am not sure why the company does not announce its intention to up-list this week, right after opening of enrollment for the last three patients in the Pilot study.
Just the announcement and preliminary communications with the NYSE:MKT would send the price well over $3, at which point they could consult with the NASDAQ:CM, if they wanted the cheaper deal.
The science is doing just as we expected -safe and effective. We need to up-list to unlock that value for shareholders, and it will be substantial.
That said, based on your and my analyses, I guess Nobody owns enough NVIV.
Sentiment: Strong Buy
The stooges are too funny. The sky is falling, the sky is falling.....LOL
First of all, there will not be any dilution until after all the punches are pulled regarding 010 & 004 phase 2 along with Trimesta. No Biotech that has pending catalysts in the short term dilutes ahead of the catalyst. You'd have a share holder revolt. They're going to wait until after all the shots are fired and the share price is at it's peak to do any dilution.
Testing has revealed that CYTOSORB beads remove various molecules relevant to inflammation in sepsis, including: TNF, IL-6, IL-10, HMGB-1, IL-8, IL-18, MCP-1, IL-2, IL-1.beta. and S100B.
S100B has been shown to be increased in the blood and CSF after TBI in humans, many studies have focused on S100B under various cerebral ischaemic conditions.
There is an apparent interaction between ß-amyloid and expression of S100B. It was shown that ß-amyloid stimulates the synthesis of both S100B mRNA and S100B protein in astrocyte cultures.39 In addition, there is accumulating epidemiological and cellular evidence of the importance of inflammation in AD. Extracellular S100B might participate in brain inflammation by activating astrocytes, microglia and neurons.
"Bigots and racists have no value in our world"
So it appears Mr. bhull zhitt story (Mr. bstaurrey) and Mr. Adolph Hitler have the same solutions to whatever they perceive to be the world's problems. Nice.
Nobear biotch slaps you down hard day after day. You must like it.
Appreciate what the company is displaying on their website and hope it reflects some type of real progress that will be communicated 3/31 along with other relevant news. Only 7 days - think I'll sit back now and wait to discern what they announce.
(Bloomberg) -- In Pakistan, it’s difficult to find a more successful money manager than Maheen Rahman.
The 39-year-old turned a loss—making asset management company into a profitable acquisition target, led her flagship equity fund to the country’s top performance and positioned her new firm for what she estimates will be a 40 percent jump in client assets this year. For all that, Rahman still struggles to prove she belongs in an industry where all 21 of her rival chief executive officers are men.
“My biggest challenge has been building a reputation and trust in a market that values grey hair and being male,” said Rahman, who oversees the equivalent of $180 million in stocks and bonds as the CEO of Alfalah GHP Investment Management Ltd. in Karachi. “After all these years, I still routinely get asked why I don’t just design clothes.”
While Rahman’s rise to the top of a financial firm would have been almost unheard of in Pakistan two decades ago, her struggle to gain the acceptance of male peers illustrates the challenge professional women still face in a country with the smallest proportion of female workers among Asia’s 15 largest economies. Investors who bet on Rahman have been rewarded with a 443 percent return from her IGI Stock Fund since its inception seven years ago, 117 percentage points more than the benchmark index and the biggest gain among 34 peers tracked by Bloomberg.